Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.87 USD
Change Today -0.27 / -1.22%
Volume 620.2K
RTRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

retrophin inc (RTRX) Snapshot

Open
$22.24
Previous Close
$22.14
Day High
$22.89
Day Low
$21.70
52 Week High
03/24/15 - $24.71
52 Week Low
10/1/14 - $7.85
Market Cap
741.7M
Average Volume 10 Days
1.8M
EPS TTM
$-4.79
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RETROPHIN INC (RTRX)

retrophin inc (RTRX) Details

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. It sells Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders; and Thiola for the treatment of cystinuria. The company also develops Sparsentan, an investigational therapeutic agent, which acts as a potent angiotensin receptor blocker, as well as endothelin receptor antagonist for the treatment of focal segmental glomerulosclerosis; RE-024, a novel small molecule to treat pantothenate kinase associated neurodegeneration; and Carbetocin for the treatment of milk let-down in post pregnant women, as well as for autism and schizophrenia. In addition, it develops RE-034, a synthetic hormone analogue of the first 24 amino acids of the 39 amino acids contained in adrenocorticotrophic hormone for the treatment of infantile spasms and nephrotic syndrome. Further, the company intends to obtain FDA approval of Chenodal for the treatment of cerebrotendinous xanthomatosis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

110 Employees
Last Reported Date: 03/11/15
Founded in 2011

retrophin inc (RTRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $323.2K
Executive Vice President of Research and Deve...
Total Annual Compensation: $430.8K
General Counsel
Total Annual Compensation: $95.8K
Compensation as of Fiscal Year 2014.

retrophin inc (RTRX) Key Developments

Retrophin Prices Offering; Mulls Acquisitions

Retrophin, Inc. (NasdaqGM:RTRX) has priced an underwritten public offering for gross proceeds of approximately $130 million. Retrophin anticipates using the net proceeds from the offering to fund its research and development efforts, acquisitions or investments in additional complementary businesses, products and technologies, including $27 million to fund the initial cash milestone payment payable in connection with the acquisition of an additional clinical asset from Asklepion Pharmaceuticals, LLC, and for general corporate purposes, including working capital.

Retrophin, Inc. Reports Earnings Results for the Fourth Quarter of 2014

Retrophin, Inc. reported earnings results for the fourth quarter of 2014. The company reported fourth quarter 2014 GAAP net loss of $29 million or $1.10 loss per share, compared with the prior-year period's $12.8 million or $0.70 loss per share. Adjusted net loss was $9.4 million, or $0.36 loss per share, versus $8.5 million, or $0.46 loss per share in the same quarter the previous year. Net product sales for the quarter were $14.1 million, compared with no reported sales for the same quarter in 2013. It narrowed down its adjusted loss year over year; it also recorded product sales compared with no product sales in the same period last year.

Tim Coughlin Joins Retrophin’s Board of Directors, Effective March 31, 2015

Retrophin, Inc. announced the addition of Tim Coughlin, C.P.A. to the Company’s Board of Directors as a fifth independent director, effective March 31, 2015. Mr. Coughlin has served as Chief Financial Officer of Neurocrine Biosciences, since 2006. Mr. Coughlin has experience in corporate accounting, finance, and operations management of companies ranging in size from start-ups through Fortune 500. Mr. Coughlin currently serves on the Board of Directors of Fate Therapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTRX:US $21.87 USD -0.27

RTRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RTRX.
View Industry Companies
 

Industry Analysis

RTRX

Industry Average

Valuation RTRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RETROPHIN INC, please visit www.retrophin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.